2.92
0.14 (5.04%)
| Penutupan Terdahulu | 2.78 |
| Buka | 2.78 |
| Jumlah Dagangan | 1,643,383 |
| Purata Dagangan (3B) | 1,621,092 |
| Modal Pasaran | 828,438,528 |
| Harga / Buku (P/B) | 2.69 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| EPS Cair (TTM) | -0.570 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.72% |
| Nisbah Semasa (MRQ) | 12.35 |
| Aliran Tunai Operasi (OCF TTM) | -107.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -91.89 M |
| Pulangan Atas Aset (ROA TTM) | -22.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Erasca, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.25 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.69% |
| % Dimiliki oleh Institusi | 84.38% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (Guggenheim, 71.23%) | Beli |
| Median | 4.50 (54.11%) | |
| Rendah | 4.00 (Stifel, 36.99%) | Beli |
| Purata | 4.50 (54.11%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 2.56 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 14 Nov 2025 | 5.00 (71.23%) | Beli | 2.58 |
| Stifel | 16 Oct 2025 | 4.00 (36.99%) | Beli | 2.53 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | Erasca to Present at the 8th Annual Evercore Healthcare Conference |
| 12 Nov 2025 | Pengumuman | Erasca Reports Third Quarter 2025 Business Updates and Financial Results |
| 06 Nov 2025 | Pengumuman | Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 |
| 04 Nov 2025 | Pengumuman | Erasca to Present at Upcoming Conferences in November |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |